Alimera outlines EU commercial strategy and raises $40m to market Iluvien
This article was originally published in Scrip
Executive Summary
Alimera Sciences will raise $40 million from the sale stock plus warrants to finance commercialization of Iluvien (fluocinolone acetonide) for the treatment of vision impairment associated with chronic diabetic macular edema (DME) in Europe, where the company intends to focus its marketing efforts while US FDA approval remains elusive.